Psychoneuroendocrinology
Volume 32, Issue 5 , Pages 464-469 , June 2007

Lithium, arginine vasopressin and the dex/CRH test in mood disordered patients

Received 1 December 2006 ,Revised 28 February 2007 ,Accepted 28 February 2007.

References 

  1. Aguilera G, Pham Q, Rabadan-Diehl C. Regulation of pituitary vasopressin receptors during chronic stress: relationship to corticotroph responsiveness. J. Neuroendocrinol. 1994;6(3):299–304
  2. Anai H, Ueta Y, Serino R, Nomura M, Kabashima N, Shibuya I, et al. Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat. Brain Res. 1997;772(1–2):161–166
  3. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 1993;14(2):76–122
  4. Baylis, P.H., 2003. Water and sodium homeostasis and their disorders. In: D.A. Warrell, C. T.M., F. J.D. (Eds.), Oxford Textbook of Medicine. Oxford, Oxford Medical Publications: 3116–3126.
  5. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999;21(6):449–456
  6. Bendz H, Sjodin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol. Dial. Transplant. 1996;11(3):457–460
  7. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am. J. Kidney Dis. 1987;10(5):329–345
  8. Bschor T, Adli M, Baethge C, Eichmannb U, Ising M, Uhr M, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology. 2002;27(3):470–478
  9. Bschor T, Baethge C, Adli M, Eichmann U, Ising M, Uhr M, et al. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. Depress. Anxiety. 2003;17(1):43–48
  10. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic–pituitary–adrenal axis and bipolar disorder. Psychiatr. Clin. North Am. 2005;28(2):469–480
  11. Dinan TG, O’Brien S, Lavelle E, Scott LV. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol. Med. 2004;34(1):169–172
  12. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev. 1996;20(3):341–358
  13. Erkut ZA, Pool C, Swaab DF. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J. Clin. Endocrinol. Metab. 1998;83(6):2066–2073
  14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version. New York: Biometrics Research; 1997;
  15. Gispen-de Wied CC, Westenberg HG, Koppeschaar HP, Thijssen JH, van Ree JM. Stimulation of the pituitary–adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects. Eur. Neuropsychopharmacol. 1992;2(4):411–419
  16. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA. 2002;16:16
  17. Guirguis AF, Taylor HC. Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature. Endocr. Pract. 2000;6(4):324–328
  18. Karssen AM, Meijer OC, Berry A, Sanjuan Pinol R, de Kloet ER. Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology. 2005;146(12):5587–5595
  19. Keck ME, Wigger A, Welt T, Muller MB, Gesing A, Reul JMHM, et al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology. 2002;26(1):94–105
  20. Lehmann EL. Nonparametrics. Statistical Methods Based on Ranks. San Francisco: Holden-Day; 1975;
  21. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J. Psychopharmacol. 2006;20(3):347–355
  22. Meynen G, Unmehopa UA, van Heerikhuize JJ, Hofman MA, Swaab DF, Hoogendijk WJ. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biol. Psychiatr. 2006;60(8):892–895
  23. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatr. 1996;53(2):137–143
  24. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994;60(4):436–444
  25. Rhodes ME, O’Toole SM, Czambel RK, Rubin RT. Male–female differences in rat hypothalamic–pituitary–adrenal axis responses to nicotine stimulation. Brain Res. Bull. 2001;54(6):681–688
  26. Ritchie JC, Belkin BM, Krishnan KR, Nemeroff CB, Carroll BJ. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol. Psychiatr. 1990;27(2):159–173
  27. Rooke P, Baylis PH. A new sensitive radioimmunoassay for plasma arginine vasopressin. J. Immunoassay. 1982;3(2):115–131
  28. Scott LV, Dinan TG. Vasopressin as a target for antidepressant development: an assessment of the available evidence. J. Affect. Disord. 2002;72(2):113–124
  29. Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, et al. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev. 2005;11(1):53–68
  30. SPSS. SPSS for Windows Version 9.0. SPSS Inc: Chicago; 1998;
  31. Stone KA. Lithium-induced nephrogenic diabetes insipidus. J. Am. Board Fam. Pract. 1999;12(1):43–47
  32. von Bardeleben U, Holsboer F, Stalla G, Muller O. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci. 1985;37(17):1613–1618
  33. Walker RJ, Weggery S, Bedford JJ, McDonald FJ, Ellis G, Leader JP. Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers. Kidney Int. 2005;67(1):291–294
  34. Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH. Hypothalamic–pituitary–adrenal axis function in patients with chronic depression. Psychol. Med. 2002;32(6):1021–1028
  35. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic–pituitary–adrenal axis function in patients with bipolar disorder. Br. J. Psychiatr. 2004;184:496–502
  36. Watson S, Gallagher P, Ferrier IN, Young AH. Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. J. Psychiatr. Res. 2006;40(4):353–359

PII: S0306-4530(07)00053-4

doi: 10.1016/j.psyneuen.2007.02.010

Psychoneuroendocrinology
Volume 32, Issue 5 , Pages 464-469 , June 2007

Article Tools